Cost-utility analysis of life-long prophylaxis with recombinant factor VIIIFc vs recombinant factor VIII for the management of severe hemophilia A in Sweden

References

• Blackwell Publishing Ltd., 2012. Available online at https://www1.wfh.org/publication/files/pdf-1472.pdf (accessed 16 November 2016)
   Google Scholar
• Berntorp E, Shapiro AD, White G, et al. Modern haemophilia care. Lancet 2012;379:1447-56
   PubMed Web of Science ®Google Scholar
• Manco-Johnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007;357:535-44
   PubMed Web of Science ®Google Scholar
• Manco-Johnson MJ, Kempton CL, Reding MT, et al. Randomized; controlled; parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART). J Thromb Haemost 2013;11:1119-27
   PubMed Web of Science ®Google Scholar
• Collins P, Faradji A, Morfini M, et al. Efficacy and safety of secondary prophylactic vs. on-demand sucrose-formulated recombinant factor VIII treatment in adults with severe hemophilia A: results from a 13-month crossover study. J Thromb Haemost 2010;8:83-9
   PubMed Web of Science ®Google Scholar
• Gringeri A, Lundin B, Von Mackensen S, et al. A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study). J Thromb Haemost 2011;9:700-10
   PubMed Web of Science ®Google Scholar
• Khawaji M, Astermark J, Berntorp E. Lifelong prophylaxis in a large cohort of adult patients with severe haemophilia: a beneficial effect on orthopaedic outcome and quality of life. Eur J Haematol 2012;88:329-35
   PubMed Web of Science ®Google Scholar
• Thornburg CD. Physicians’ perceptions of adherence to prophylactic clotting factor infusions. Haemophilia 2007;14:25-9
   PubMed Web of Science ®Google Scholar
• Schrijvers LH, Uitslager N, Schuurmans MJ, et al. Barriers and motivators of adherence to prophylactic treatment in haemophilia: a systematic review. Haemophilia 2013;19:355-61
   PubMed Web of Science ®Google Scholar
• Di Paola J, Smith MP, Klamroth R, et al. ReFacto® 1 and Advate® 2: a single-dose; randomized; two-period crossover pharmacokinetics study in subjects with haemophilia A. Haemophilia 2007;13:124-30
   PubMed Web of Science ®Google Scholar
• Srivastava A, Brewer AK, Mauser-Bunschoten EP, et al. Guidelines for the management of hemophilia. Haemophilia 2013;19:e1-47
   PubMed Web of Science ®Google Scholar
• Hacker MR, Geraghty S, Manco-Johnson M. Barriers to compliance with prophylaxis therapy in haemophilia. Haemophilia 2001;7:392-6
   PubMed Web of Science ®Google Scholar
• Frampton JE. Efmoroctocog slfa: a review in haemophilia A. Drugs 2016;76:1281-91
   PubMed Web of Science ®Google Scholar
• Mahlangu J, Powell JS, Ragni MV, et al. Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. Blood 2014;123:317-25
   PubMed Web of Science ®Google Scholar
• Young G, Mahlangu J, Kulkarni R, et al. Recombinant factor VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia A. J Thromb Haemost 2015;13:967-77
   PubMed Web of Science ®Google Scholar
• Berntorp E, Negrier C, Gozzi P, et al. Dosing regimens; FVIII levels and estimated haemostatic protection with special focus on rFVIIIFc. Haemophilia 2016;22:389-96
   PubMed Web of Science ®Google Scholar
• The Pharmaceutical Benefits Board. General guidelines for economic evaluations from the Pharmaceutical Benefits Board (LFNAR 2003:2). Dental and Pharmaceutical Benefits Agency; 2003. Available online at: http://www.tlv.se/Upload/English/Guidelines-for-economic-evaluations-LFNAR-2003-2.pdf (accessed 21 April 2017)
   Google Scholar
• Valentino LA, Mamonov V, Hellmann A, et al. A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management. J Thromb Haemost 2012;10:359-67
   PubMed Web of Science ®Google Scholar
• Nolan B, Mahlangu J, Perry D, et al. Long-term safety and efficacy of recombinant factor VIII Fc fusion protein (rFVIIIFc) in subjects with haemophilia A. Haemophilia 2016;22:72-80
   PubMed Web of Science ®Google Scholar
• Lorio A, et al. Haemophilia 2017; 23(3): 408-416
   PubMed Web of Science ®Google Scholar
• Powell J, Martinowitz U, Windyga J, et al. Efficacy and safety of prophylaxis with once-weekly BAY 79–4980 compared with thrice-weekly rFVIII-FS in haemophilia A patients. Thromb Haemost 2012;108:913-22
   PubMed Web of Science ®Google Scholar
• Blanchette VS, Shapiro AD, Liesner RJ, et al. Plasma and albumin-free recombinant factor VIII: pharmacokinetics; efficacy and safety in previously treated pediatric patients. J Thromb Haemost 2008;6:1319-26
   PubMed Web of Science ®Google Scholar
• Kulkarni R, Karim FA, Glamocanin S, et al. Results from a large multinational clinical trial (guardianTM3) using prophylactic treatment with turoctocog alfa in paediatric patients with severe haemophilia A: safety; efficacy and pharmacokinetics. Haemophilia 2013;19:698-705
   PubMed Web of Science ®Google Scholar
• Klukowska A, Szczepański T, Vdovin V, et al. Novel; human cell line-derived recombinant factor VIII (Human-cl rhFVIII; Nuwiq®) in children with severe haemophilia A: efficacy; safety and pharmacokinetics. Haemophilia 2016;22:232-9
   PubMed Web of Science ®Google Scholar
• Nolan B, Mahlangu J, Perry D, et al. Long-term safety and efficacy of recombinant factor VIII Fc fusion protein (rFVIIIFc) in subjects with haemophilia A. Haemophilia 2016;22:72-80
   PubMed Web of Science ®Google Scholar
• Statistics Sweden. Längd; vikt och BMI. Medelvärden samt felmarginal (95-procentigt konfidensintervall) [Internet]. Källa: SCB; Undersökningarna av levnadsförhållanden (ULF/SILC); 2015. Available at: http://www.scb.se/sv_/Hitta-statistik/Statistik-efter-amne/Levnadsforhalla-nden/Levnadsforhallanden/Undersokningarna-av-levnadsforhallanden-ULFSILC/12202/12209/ULFSILC-2010-/Hal-sa/363378/
   Google Scholar
• Läkemedelsförmånsverket T. Tandvards & lakemedelsformansverket TLV [Internet]. Tandvårds- och läkemedelsförmånsverket; 2015. Available at: http://www.tlv.se/In-English/price-database/
   Google Scholar
• Neufeld EJ, Recht M, Sabio H, et al. Effect of acute bleeding on daily quality of life assessments in patients with congenital hemophilia with inhibitors and their families: observations from the dosing observational study in hemophilia. JVAL 2012;15:916-25
   Google Scholar
• Eriksson E, Nordlund A. Hälsa och hälsorelaterad livskvalitet mätt med EQ-5D och SF-36 i Östergötlands och Kalmar län: Resultat från befolkningsenkäterna. Rapp kan beställas från; Folk Cent; 2002
   Google Scholar
• Carlsson et al. EAHAD conference proceedings, 1-3 February 2017, Paris, France
   Google Scholar
• Statistics Sweden. Livslängdstabell för 2013; uppdelat på män och kvinnor [Internet]. Källa: Statistiska centralbyrån; 2015. Available at: http://www.scb.se/Statistik/BE/BE0101/2013A02F/Be0101Livslängdstabel-ler_13.xls
   Google Scholar
• Reitter S, Waldhoer T, Vutuc C, et al. Survival in a cohort of patients with haemophilia at the haemophilia care center in Vienna; Austria; from 1983 to 2006. Haemophilia 2009;15:888-93
   PubMed Web of Science ®Google Scholar
• Ramsberg J, Odeberg S, Engstrom A, et al. Examining the quality of health economic analyses submitted to the Pharmaceutical Benefits Board in Sweden. Eur J Heal Econ 2004;5:351-6
   PubMedGoogle Scholar
• Berntorp E, Dolan G, Hay C, et al. European retrospective study of real-life haemophilia treatment. Haemophilia 2017;23:105-14
   PubMed Web of Science ®Google Scholar
• Keepanasseril A, et al. Haemophilia 2017;23(4):e365-e367
   PubMed Web of Science ®Google Scholar
• Tarantino MD, Collins PW, Hay CRM, et al. Clinical evaluation of an advanced category antihaemophilic factor prepared using a plasma/albumin-free method: pharmacokinetics; efficacy; and safety in previously treated patients with haemophilia A1. Haemophilia 2004;10:428-37
   PubMed Web of Science ®Google Scholar
• Recht M, Nemes L, Matysiak M, et al. Clinical evaluation of moroctocog alfa (AF-CC); a new generation of B-domain deleted recombinant factor VIII (BDDrFVIII) for treatment of haemophilia A: demonstration of safety; efficacy; and pharmacokinetic equivalence to full-length recombinant factor V. Haemophilia 2009;15:869-80
   PubMed Web of Science ®Google Scholar
• Lentz SR, Misgav M, Ozelo M, et al. Results from a large multinational clinical trial (guardianTM1) using prophylactic treatment with turoctocog alfa in adolescent and adult patients with severe haemophilia A: Safety and efficacy. Haemophilia 2013;19:691-7
   PubMed Web of Science ®Google Scholar
• Lissitchkov T, Hampton K, von Depka M, et al. Novel; human cell line-derived recombinant factor VIII (human-cl rhFVIII; Nuwiq®) in adults with severe haemophilia A: Efficacy and safety. Haemophilia 2016;22:225-31
   PubMed Web of Science ®Google Scholar
• Pollmann H, Externest D, Ganser A, et al. Efficacy; safety and tolerability of recombinant factor VIII (REFACTO) in patients with haemophilia A: Interim data from a postmarketing surveillance study in Germany and Austria. Haemophilia 2007;13:131-43
   PubMed Web of Science ®Google Scholar